Eton director awarded options and RSUs

Eton Pharmaceuticals director Charles J. Casamento reported new equity awards.

Rhea-AI Filing Summary

Eton Pharmaceuticals director Charles J. Casamento reported new equity awards. On January 12, 2026, he received an employee stock option covering 12,196 shares of Eton common stock with an exercise price of $15.47 per share. According to the filing, these option shares vest quarterly over 12 months from the grant date and become fully vested and exercisable on January 12, 2027.

On the same date, he was also granted 7,757 restricted stock units. Each RSU represents a contingent right to receive one share of Eton common stock. These RSUs vest in a single annual installment beginning January 12, 2027, conditioned on his continued employment with the company on the vesting date. Following these grants, he beneficially owned 295,171 derivative securities related to options and 302,928 derivative securities related to restricted stock units.

Insider Trade Summary

Grant/Award: 19,953 shares

Grant/Award 2 txns

Insider CASAMENTO CHARLES J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	12,196	$0.00	$0.00
Grant/Award	Restricted Stock Units	7,757	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 295,171 contracts (Direct); Restricted Stock Units — 302,928 contracts (Direct)

Footnotes (3)

1. F1. The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on January 12, 2027.
2. F2. Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock.
3. F3. The restricted stock units vest in one annual installment beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ETON director Charles J. Casamento report?

He reported the grant of an employee stock option for 12,196 shares and 7,757 restricted stock units of Eton Pharmaceuticals common stock on January 12, 2026.

What are the key terms of the ETON stock options granted to Charles J. Casamento?

The employee stock option covers 12,196 shares at an exercise price of $15.47 per share and vests quarterly over 12 months, becoming fully vested and exercisable on January 12, 2027.

How do the restricted stock units granted to the ETON director vest?

The 7,757 restricted stock units vest in one annual installment beginning January 12, 2027, contingent on the reporting person being employed by Eton Pharmaceuticals on the vesting date.

How many derivative securities does the ETON director hold after these transactions?

After the reported grants, the director beneficially owned 295,171 derivative securities related to options and 302,928 derivative securities related to restricted stock units.

Does each ETON restricted stock unit equal one share of common stock?

Yes. The filing states that each restricted stock unit represents a contingent right to receive one share of ETON common stock.

What role does Charles J. Casamento have at Eton Pharmaceuticals (ETON)?

He is reported as a director of Eton Pharmaceuticals and is not listed as an officer or 10% owner in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/14/2026 - 06:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CASAMENTO CHARLES J

(Last) (First) (Middle)

C/O ETON PHARMACEUTICALS, INC.

21925 W. FIELD PARKWAY, SUITE 235

(Street)

DEERPARK IL 60010-7208

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Eton Pharmaceuticals, Inc. [ ETON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$15.47	01/12/2026		A		12,196		(1)	01/11/2036	Common Stock	12,196	$0	295,171	D
Restricted Stock Units	(2)	01/12/2026		A		7,757		(3)	(3)	Common Stock	7,757	$0	302,928	D

Explanation of Responses:

1. The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on January 12, 2027.

2. Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock.

3. The restricted stock units vest in one annual installment beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting.

Remarks:

The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.

	/s/ James R. Gruber	01/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.